Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.

Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, Panico S, Peeters PH, Pike MC, Riboli E, Tjonneland A, Travis R, Trichopoulos D, Wacholder S, Ziegler RG.

Cancer Res. 2007 Mar 1;67(5):1893-7. Epub 2007 Feb 26.

2.

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2734-44. doi: 10.1158/1055-9965.EPI-09-0496. Epub 2009 Sep 29.

3.

A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort.

Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J, Henderson BE.

Hum Mol Genet. 2003 Oct 15;12(20):2679-92. Epub 2003 Aug 27.

PMID:
12944421
4.

Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.

Cai Q, Kataoka N, Li C, Wen W, Smith JR, Gao YT, Shu XO, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):27-32. doi: 10.1158/1055-9965.EPI-07-0688.

5.

Association between CYP19A1 polymorphisms and sex hormones in postmenopausal Japanese women.

Kidokoro K, Ino K, Hirose K, Kajiyama H, Hosono S, Suzuki T, Kawase T, Hiraki A, Hamajima N, Tanaka H, Tajima K, Kikkawa F, Matsuo K.

J Hum Genet. 2009 Feb;54(2):78-85. doi: 10.1038/jhg.2008.11. Epub 2009 Jan 16.

PMID:
19158807
6.

A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.

Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO.

BMC Med Genet. 2007 Dec 1;8:72.

7.

HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.

Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):213-9.

8.

Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.

Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):242-7. doi: 10.1158/1055-9965.EPI-08-0689.

9.

Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.

Straume AH, Knappskog S, Lønning PE.

J Steroid Biochem Mol Biol. 2012 Jan;128(1-2):69-75. doi: 10.1016/j.jsbmb.2011.08.015. Epub 2011 Sep 16.

PMID:
21939764
10.

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46.

11.

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.

Lunardi G, Piccioli P, Bruzzi P, Notaro R, Lastraioli S, Serra M, Marroni P, Bighin C, Mansutti M, Puglisi F, Porpiglia M, Ponzone R, Bisagni G, Garrone O, Cavazzini G, Clavarezza M, Del Mastro L.

Breast Cancer Res Treat. 2013 Jan;137(1):167-74. doi: 10.1007/s10549-012-2306-z. Epub 2012 Nov 6.

12.

Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.

Boone SD, Baumgartner KB, Baumgartner RN, Connor AE, Pinkston CM, Rai SN, Riley EC, Hines LM, Giuliano AR, John EM, Stern MC, Torres-Mejía G, Wolff RK, Slattery ML.

Cancer Causes Control. 2014 Nov;25(11):1461-71. doi: 10.1007/s10552-014-0448-5. Epub 2014 Aug 5.

13.

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium.

PLoS One. 2008 Jul 2;3(7):e2578. doi: 10.1371/journal.pone.0002578.

14.

Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.

Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K, Le Marchand L, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1021-5.

15.

The aromatase gene (CYP19A1) variants and circulating hepatocyte growth factor in postmenopausal women.

Lin JH, Gunter MJ, Manson JE, Rexrode KM, Cook NR, Kraft P, Cochrane BB, Chlebowski RT, Ho GY, Zhang SM.

PLoS One. 2012;7(7):e42079. doi: 10.1371/journal.pone.0042079. Epub 2012 Jul 25.

16.

Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.

Umamaheswaran G, Dkhar SA, Kalaivani S, Anjana R, Revathy M, Jaharamma M, Shree KM, Kadambari D, Adithan C.

Med Oncol. 2013;30(3):665. doi: 10.1007/s12032-013-0665-x. Epub 2013 Jul 28.

PMID:
23893151
17.

Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.

Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1993-7.

18.

Significant association between common polymorphisms in the aromatase gene CYP19A1 and bone mineral density in postmenopausal women.

Mullin BH, Carter KW, Lewis JR, Ingley E, Wilson SG, Prince RL.

Calcif Tissue Int. 2011 Dec;89(6):464-71. doi: 10.1007/s00223-011-9535-8. Epub 2011 Sep 28.

PMID:
21952832
19.

A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.

Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM, Bae JY, Kim S, Shin ES, Lee JE, Shin HJ, Kim SW, Kim SW, Noh DY.

Clin Cancer Res. 2005 Jul 1;11(13):4775-8.

20.

Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women.

Tao MH, Cai Q, Zhang ZF, Xu WH, Kataoka N, Wen W, Xiang YB, Zheng W, Shu XO.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):943-9.

Supplemental Content

Support Center